Biosimilars: New guns for the treatment of rheumatological patients? Beyond Rheumatology 2019; 1 (1): e255 DOI: 10.4081/br.2019.3
The journey of canakinumab; on- and off-label indications Beyond Rheumatology 2019; 1 (1): e256 DOI: 10.4081/br.2019.4